← Back to Clinical Trials
Recruiting NCT06461780

NCT06461780 Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06461780
Status Recruiting
Phase
Sponsor Taipei Veterans General Hospital, Taiwan
Condition Cancer
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2024-03-18
Primary Completion 2028-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2024-03-18 with a primary completion date of 2028-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of life. Therefore, the aims of this program are to (1) explore the immune-related adverse event (irAE) severity, distress, financial toxicity, and quality of life and examine the psychometric testing of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM); (2) establish the LINE group for assessing irAE severity and change trajectory of quality of life in one-year follow-up and (3) combined retrospective chart review and the finding in aim (2) to develop the risk prediction model in order to identify the high risk population.

Eligibility Criteria

Inclusion Criteria: * (1) Patients diagnose cancer and are informed * (2) Aged ≥18 years old * (3) Conscious clear and able to communicate

Contact & Investigator

Central Contact

I-Wen Chang, PHD

✉ iwchang@vghtpe.gov.tw

📞 886-2-2875-7193

Principal Investigator

I-Wen Chang, PHD

STUDY CHAIR

Taipei Veterans General Hospital, Taiwan

Frequently Asked Questions

Who can join the NCT06461780 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06461780 currently recruiting?

Yes, NCT06461780 is actively recruiting participants. Contact the research team at iwchang@vghtpe.gov.tw for enrollment information.

Where is the NCT06461780 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT06461780 clinical trial?

NCT06461780 is sponsored by Taipei Veterans General Hospital, Taiwan. The principal investigator is I-Wen Chang, PHD at Taipei Veterans General Hospital, Taiwan. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology